Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells
/in Chronic Virus Hepatitis, International Publications /von 2007-03-15 / Clin. Exp. Immunol. 2007 Jun;148(3):494-500Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
/in International Publications, Malignant Lymphoma /von 2007-03-14 / J Transl Med 2007 Mar;5:16Point: Hyperthermia with radiation for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications /von 2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):339-44Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications /von 2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-8Oncolytic virus therapy–foreword
/in International Publications, Newcastle Disease Virus /von 2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-5Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trial
/in International Publications, Prostate Cancer /von 2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-4Dendritic cell-based immunotherapy of malignant melanoma: success and limitations
/in International Publications, Malignant Melanoma /von 2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-6
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution